Drugs / AZD6621
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07192614 | Sep 2025 → Mar 2029 expected | prostate cancer | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07192614 ↗ |
| Target | CD8 | “targets STEAP2, CD3, and CD8” NCT07192614 ↗ |
| Target | STEAP2 | “targets STEAP2” NCT07192614 ↗ |